Business
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader Delivery of CAR T at Biologic-Like ScaleInterim Futility Analysis Evaluating MRD Clearance and Early Safety Results Planned for April 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID
About this update from Allogene Therapeutics, Inc.
[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QCsYA1reL6jmKogB1ZpqzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)","length":149,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader Delivery of CAR T at Biologic-Like Scale","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Interim Futility Analysis Evaluating MRD Clearance and Early Safety Results Planned for April 2026","length":98,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":284,"olType":false}]},{"val":[{"type":"text","content":"Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID)","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ALLO-329, a Dual CD19/CD70 CAR, Harnesses the Dagger® Technology to Reduce or Eliminate Lymphodepletion","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"RESOLUTION Basket Trial in Rheumatology Enrolling in the Dose Escalation Phase with Proof-of-Concept Data Planned for June 2026","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":230,"olType":false}]},{"val":[{"type":"text","content":"Ended Q4 2025 with $258.3 Million in Cash, Cash Equivalents and Investments","length":85,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Extended the Cash Runway into Q1 2028","length":37,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":37,"olType":false}]},{"val":[{"type":"text","content":"Conference Call and Webcast Scheduled for Today at 2:00 PM PT/5:00 PM ET","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length...